NovaVive Inc. - Canine

Home
Canada
Napanee, ON
NovaVive Inc. - Canine

NovaVive offers a regulator-approved immunotherapy for canine mammary cancer in the USA and Canada. NovaVive Inc.

is an animal health immunobiology company with a regulator-approved canine cancer product available to veterinarians in CA and the US.

04/10/2026

Immunocidin® is well tolerated in dogs, including aged patients and those with chronic cardiovascular or renal disease.

The product is approved for intratumoral treatment of canine mammary tumors, but research supports additional routes of administration for veterinarians (in consultation with NovaVive).

Immunocidin may be used as a standalone treatment or in combination with surgery and other therapies, depending on clinical goals.

View full product information and clinical resources at NovaVive.ca/products.

03/31/2026

For dogs whose cancer has progressed beyond standard therapies, Immunocidin® can provide palliative support to help maintain quality of life. Safe for use in all veterinary clinics across the USA and Canada, Immunocidin® can be administered intravenously or directly into tumors, allowing veterinarians to tailor care to each dog’s needs.

This approach provides families with peace of mind, knowing their pet’s comfort and well-being remain a priority while still benefiting from an approved immunotherapy.

Visit NovaVive.ca/products to learn more or ask your veterinarian about Immunocidin®.

03/27/2026

Immunocidin® is approved in the USA and Canada for the treatment of canine mammary tumors and mammary adenocarcinoma. It has a proven safety record and can be administered intratumorally or intravenously under veterinary supervision.

Research shows that Immunocidin® is well-tolerated, with minimal adverse effects, making it a reliable option for veterinarians to support dogs diagnosed with mammary cancer.

Learn more at NovaVive.ca/products.

03/25/2026

In Loving Memory of Samson 🐾

Samson was a 12-year-old mixed breed from Fort Myers, FL who was diagnosed with osteosarcoma in July 2022 and underwent amputation of his right forelimb. Samson was treated with Immunocidin® therapy and passed away on March 1st, 2026... 185 weeks after starting treatment.

“I will forever be grateful to you and everyone who helped him to be able to survive as long as he did.” – Samson’s owner

03/18/2026

NovaVive is actively researching how Immunocidin® can help dogs with osteosarcoma (bone cancer). In our ongoing North American pilot study, several dogs have been receiving Immunocidin therapy for multiple years—one for over 4 years, demonstrating encouraging long-term survival and quality of life.

This study highlights the potential of Immunocidin® to expand beyond mammary cancer and provide hope for dogs with other tumor types. Veterinarians interested in exploring Immunocidin® for osteosarcoma can connect with the NovaVive technical team to evaluate individualized treatment approaches.

Learn more at NovaVive.ca/canine-research.

02/27/2026

Did you know? 🐶
• The U.S. dog population exceeds 89 million, and 1 in 15 dogs is diagnosed with cancer each year.
• Neoplasia is the leading cause of death across all dog breeds.
• Mammary tumors are common in female dogs, with roughly 50% being malignant.
• Mammary tumors are more frequent than skin or connective tissue tumors and account for 25% of all recorded tumors.
• Mammary cancer is the most commonly diagnosed tumor in intact female dogs older than seven years.

Immunocidin® is an approved immunotherapy for mammary tumors. Its intratumoral approach provides a natural, well-tolerated option for dogs, offering veterinarians a treatment alternative in cases where surgery or chemotherapy may not be ideal.

Pet owners and veterinarians can learn more at NovaVive.ca/Products.

02/26/2026

Dolly sadly passed earlier this month. NovaVive was pleased to help her live comfortably with Immunocidin therapy for more than four years after her cancer diagnosis.

Immunocidin immunotherapy is regulator-approved in the USA and Canada for the treatment of canine mammary cancer, but it is being used experimentally to treat a variety of other cancer types, including osteosarcoma.

Immunocidin has also proven helpful as a palliative (end-of-life) support for dogs when treatment is no longer an option.

Learn more at NovaVive.ca/products or ask your veterinarian to contact us.

02/24/2026

For dogs that are older or at higher surgical risk, Immunocidin® offers an in-clinic treatment option. Administered directly to the tumor, it is well-tolerated and requires no special handling for clinic staff.

Veterinarians may combine it with surgery, chemotherapy, or use it alone, depending on the dog’s individual needs. Protocols are adjusted based on response to maximize comfort and care.

Additional information, including treatment guidance, is available for veterinarians directly from NovaVive.

02/20/2026

While Immunocidin® is regulator-approved for canine mammary tumors, veterinarians have explored its use in other tumor types such as osteosarcoma, hemangiosarcoma, and soft tissue sarcoma. It may also be used to support comfort and palliation, particularly in advanced cases.

Each case is unique, and treatment decisions are made collaboratively between vet and pet owner. NovaVive provides guidance to help tailor the approach.

Learn more and download the full product brochure at NovaVive.ca/Products.

02/10/2026

From Trussville, Alabama, Mia was diagnosed Transitional Cell Carcinoma (TCC) in the bladder. Surgery wasn’t an option due to her health, so her vet started her on pain management and Immunocidin® therapy.

In just 10 days, the tumor had shrunk by ~90% - with no side effects! Mia’s comfort and quality of life improved, giving her more time to enjoy the things she loves.

💛 Thanks to Immunocidin and Mia’s open-minded vet, families now have hope for treating cancer safely, effectively, and affordably.

📌 Name: Mia | Age: 16 | Treatment: Immunocidin (~2 weeks)

01/21/2026

Immunocidin immunotherapy is approved by regulators in the USA and Canada for the treatment of canine mammary cancer.
NovaVive continues to explore other cancers for which Immunocidin may be effective. One of these is osteosarcoma (bone cancer).

Learn more about Immunocidin research at http://novavive.ca/canine-research.

01/08/2026

Cancer is the leading cause of death in senior dogs in North America. The Animal Cancer Foundation in the U.S. estimates that approximately 6 million dogs are diagnosed with cancer in the U.S. alone each year. About 40% of these will die from the disease annually.

Immunocidin® is our regulator-approved anticancer immunotherapy for the treatment of canine mammary tumors and mammary adenocarcinoma. It is approved and available in the U.S. and Canada.

NovaVive has an ongoing program exploring other cancers for which Immunocidin may be effective. Veterinarians who are interested in exploring Immunocidin as a treatment option are in regular contact with the NovaVive technical team to consider the best approaches. Each case is unique and responds differently to therapy.

For more information, visit NovaVive.ca/products.

Address

15 Dairy Avenue
Napanee, ON
K7R1M4

Website

http://www.NovaVive.ca/

Alerts

Be the first to know and let us send you an email when NovaVive Inc. - Canine posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to NovaVive Inc. - Canine:

Shortcuts

Want your practice to be the top-listed Clinic in Napanee?